Dihydromyricetin Modulates Nrf2 and NF-κB Crosstalk to Alleviate Methotrexate-Induced Lung Toxicity
-
Published:2023-03-23
Issue:4
Volume:16
Page:481
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Matouk Asmaa I.1, Awad Eman M.1, El-Tahawy Nashwa F. G.2ORCID, El-Sheikh Azza A. K.3ORCID, Anter Aliaa1
Affiliation:
1. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia 61511, Egypt 2. Department of Histology and Cell Biology, Faculty of Medicine, Minia University, El-Minia 61511, Egypt 3. Basic Health Sciences Department, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
Abstract
Background: Methotrexate (MTX) is an effective anticancer, anti-inflammatory, and immunomodulatory agent. However, it induces a serious pneumonitis that leads to irreversible fibrotic lung damage. This study addresses the protective role of the natural flavonoid dihydromyricetin (DHM) against MTX-induced pneumonitis via modulation of Nrf2/NF-κB signaling crosstalk. Methods: Male Wistar rats were divided into 4 groups: control, which received the vehicle; MTX, which received a single MTX (40 mg/kg, i.p) at day 9 of the experiment; (MTX + DHM), which received oral DHM (300 mg/kg) for 14 days and methotrexate (40 mg/kg, i.p) on the 9th day; and DHM, which received DHM (300 mg/kg, p.o) for 14 days. Results: Lung histopathological examination and scoring showed a decline in MTX-induced alveolar epithelial damage and decreased inflammatory cell infiltration by DHM treatment. Further, DHM significantly alleviated the oxidative stress by decreasing MDA while increasing GSH and SOD antioxidant levels. Additionally, DHM suppressed the pulmonary inflammation and fibrosis through decreasing levels of NF-κB, IL-1β, and TGF-β1 while promoting the expression of Nrf2, a positive regulator of antioxidant genes, and its downstream modulator, HO-1. Conclusion: This study identified DHM as a promising therapeutic target against MTX-induced pneumonitis via activation of Nrf2 antioxidant signaling while suppressing the NF-κB mediated inflammatory pathways.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference96 articles.
1. Toward a better understanding of methotrexate;Kremer;Arthritis Rheum.,2004 2. Bedoui, Y., Guillot, X., Selambarom, J., Guiraud, P., Giry, C., Jaffar-Bandjee, M.C., Ralandison, S., and Gasque, P. (2019). Methotrexate an Old Drug with New Tricks. Int. J. Mol. Sci., 20. 3. Kozminski, P., Halik, P.K., Chesori, R., and Gniazdowska, E. (2020). Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers. Int. J. Mol. Sci., 21. 4. Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis;Cronstein;Pharmacol. Rev.,2005 5. Methotrexate in systemic lupus erythematosus: A systematic review of its efficacy;Sakthiswary;Lupus,2014
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|